Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients.

ABSTRACT:

Objective

To estimate the absolute treatment effect of statin therapy on major adverse cardiovascular events (MACE; myocardial infarction, stroke and vascular death) for the individual patient aged ≥70 years.

Methods

Prediction models for MACE were derived in patients aged ≥70 years with (n = 2550) and without (n = 3253) vascular disease from the "PROspective Study of Pravastatin in Elderly at Risk" (PROSPER) trial and validated in the "Secondary Manifestations of ARTerial disease" (SMART) cohort study (n = 1442) and the "Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm" (ASCOT-LLA) trial (n = 1893), respectively, using competing risk analysis. Prespecified predictors were various clinical characteristics including statin treatment. Individual absolute risk reduc

SUBMITTER: Stam-Slob MC 

PROVIDER: S-EPMC5226996 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature